358 related articles for article (PubMed ID: 26557901)
1. Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.
Peters GJ
Ther Adv Med Oncol; 2015 Nov; 7(6):340-56. PubMed ID: 26557901
[TBL] [Abstract][Full Text] [Related]
2. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Temmink OH; Prins HJ; van Gelderop E; Peters GJ
Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.
Temmink OH; Emura T; de Bruin M; Fukushima M; Peters GJ
Cancer Sci; 2007 Jun; 98(6):779-89. PubMed ID: 17441963
[TBL] [Abstract][Full Text] [Related]
4. TAS-102, a novel antitumor agent: a review of the mechanism of action.
Lenz HJ; Stintzing S; Loupakis F
Cancer Treat Rev; 2015 Nov; 41(9):777-83. PubMed ID: 26428513
[TBL] [Abstract][Full Text] [Related]
5. TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies.
Chakrabarti S; Wintheiser G; Tella SH; Oxencis C; Mahipal A
Pharmacol Ther; 2021 Aug; 224():107823. PubMed ID: 33667525
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan BM; Hochster HS; Lenz HJ
Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
[TBL] [Abstract][Full Text] [Related]
7. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K
Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072
[TBL] [Abstract][Full Text] [Related]
8. New oxaliplatin-based combinations in the treatment of colorectal cancer.
Cassidy J; Hochster H
Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
10. TAS-102: a novel antimetabolite for the 21st century.
Uboha N; Hochster HS
Future Oncol; 2016 Jan; 12(2):153-63. PubMed ID: 26616466
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
12. The role of capecitabine in locally advanced rectal cancer treatment: an update.
Fernández-Martos C; Nogué M; Cejas P; Moreno-García V; Machancoses AH; Feliu J
Drugs; 2012 May; 72(8):1057-73. PubMed ID: 22621694
[TBL] [Abstract][Full Text] [Related]
13. Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression.
Matsuoka K; Nakagawa F; Kobunai T; Takechi T
Oncotarget; 2018 Mar; 9(17):13438-13450. PubMed ID: 29568368
[TBL] [Abstract][Full Text] [Related]
14. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Emura T; Murakami Y; Nakagawa F; Fukushima M; Kitazato K
Int J Mol Med; 2004 Apr; 13(4):545-9. PubMed ID: 15010854
[TBL] [Abstract][Full Text] [Related]
15. Review on TAS-102 development and its use for metastatic colorectal cancer.
Mota JM; Fonseca LG; Braghiroli MI; Hoff PM
Crit Rev Oncol Hematol; 2016 Aug; 104():91-7. PubMed ID: 27296058
[TBL] [Abstract][Full Text] [Related]
16. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
17. Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer.
Jonker D; Rumble RB; Maroun J;
Curr Oncol; 2006 Oct; 13(5):173-84. PubMed ID: 22792014
[TBL] [Abstract][Full Text] [Related]
18. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Pfeiffer P; Yilmaz M; Möller S; Zitnjak D; Krogh M; Petersen LN; Poulsen LØ; Winther SB; Thomsen KG; Qvortrup C
Lancet Oncol; 2020 Mar; 21(3):412-420. PubMed ID: 31999946
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.
Tsukihara H; Nakagawa F; Sakamoto K; Ishida K; Tanaka N; Okabe H; Uchida J; Matsuo K; Takechi T
Oncol Rep; 2015 May; 33(5):2135-42. PubMed ID: 25812794
[TBL] [Abstract][Full Text] [Related]
20. TAS-102, the first "cardio-gentle" fluoropyrimidine in the colorectal cancer landscape?
Petrelli F; Barni S; Bertocchi P; Zaniboni A
BMC Cancer; 2016 Jul; 16():386. PubMed ID: 27377645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
